First approval in the world for allogeneic cell therapy to treat corneal endothelial disease SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its novel … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Electrophysiology Diagnostic Catheters Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures and Forecast, 2015-2033” report has been added to ResearchAndMarkets.com’s offering. The report is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area. The model discusses in detail the impact of COVID-19 … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Medical Device Coatings: Global Markets” report has been added to ResearchAndMarkets.com’s offering. Medical device coating refers to the application of a layer or layers of material on a medical device to enhance its properties and performance. These coatings are used to improve the biocompatibility of the device with the human body, reduce the … [Read more…]
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds. PureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTech. Transaction provides further non-dilutive capital for PureTech’s growing … [Read more…]
Restructuring of the Company’s debt postpones initiation of repayments to Q1 2025, to be repaid with positive net royalty1 flow to Poxel anticipated to start in Sumitomo Pharma’s FY20242 based on the strong growth trajectory of TWYMEEG® (Imeglimin) sales New equity-linked financing facility with IRIS and an initial drawdown of EUR 3.5 million Cash runway … [Read more…]
The Company announced today the extension of the cash runway through Q2 2025 based upon a debt restructuring agreement and a new equity-linked financing facility Restructuring of the Company’s debt postpones initiation of repayments until Q1 2025, to be repaid with positive net royalty1 flow to Poxel anticipated to start in Sumitomo Pharma’s FY20242 based … [Read more…]
Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET® program and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in Sézary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with … [Read more…]
TOKYO–(BUSINESS WIRE)–Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) today announces that Norges Bank has terminated its observation on Kirin Holdings on March 22 2023, recognizing the completion of the Myanmar business transfer. 1. Background Based on a recommendation of Norway’s Council on Ethics*1, Norges Bank placed Kirin Holdings under observation with the possibility of exclusion from … [Read more…]
MINNEAPOLIS–(BUSINESS WIRE)–FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022 after market closes on Thursday, March 30, 2023. Management will host a conference call to discuss fourth quarter and full … [Read more…]
Another Year of Strong Performance Robust EPS Expansion Guidance Achievement NOVA LIMA, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA) (“Afya” or the “Company”), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the fourth quarter and full-year period ended December 31, 2022. Financial results are expressed in … [Read more…]
